The Financial Times reported that the rise of large language models and AI agents drove DeepMind to overhaul its research organization and strategy . The belief is that general-purpose AI can deliver broader scientific impact than dedicated tools like AlphaFold.
The majority of the original authors of the AlphaFold papers were reassigned to other departments over the last year . They were moved to projects built around the Gemini LLM, as well as to work in enzyme design, nuclear fusion, genomics, and AI coding .
Some team members were shifted to Isomorphic Labs, Alphabet's drug-discovery company .
In June 2026, John Jumper — who won the 2024 Nobel Prize in Chemistry for AlphaFold — announced he was leaving DeepMind after nearly nine years to join Anthropic . Shortly after, two other AlphaFold co-authors, Jonas Adler and Alexander Pritzel, followed him to Anthropic . In total, nearly a quarter of the original full-time DeepMind authors of the AlphaFold paper have now left the company entirely .
DeepMind is betting that Gemini-powered AI agents can automate and accelerate scientific discovery across biology, chemistry, physics, and materials science more effectively than one-off models like AlphaFold .
The AlphaFold protein structure database (covering 200 million+ proteins) and the technology itself remain available. The move does not retire the product — it ends the dedicated team that built it .
Critics argue that disbanding a Nobel-winning team signals a willingness to sacrifice deep scientific specialization for the race to build the most capable general-purpose AI system, potentially slowing progress in areas like drug discovery that relied on AlphaFold's focused expertise .
The departure of top AlphaFold scientists to Anthropic — and the parallel loss of Gemini co-lead Noam Shazeer to OpenAI — illustrates a wider pattern. The most intense competition in AI today is around general-purpose agents and foundation models, and researchers with deep expertise in any subfield are being lured to work on those core challenges.
DeepMind's move mirrors decisions at other labs: domain-specific tools (protein folding, weather prediction, game-playing AIs) are being de-prioritized as companies concentrate compute, talent, and funding on the race to build the most capable general AI agents. A single general-purpose "scientist AI" is seen as offering a larger competitive payoff than maintaining many narrow expert systems.